---
schema_version: "secwatch.filing_event.v1"
accession: "0001846253-26-000035"
form_type: "8-K"
ticker: "OABI"
cik: "0001846253"
company_name: "OmniAb, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:01:23.580411+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OmniAb Q1 revenue $14.4M vs $4.2M YoY; raises 2026 guidance

## Summary
- Revenue Q1 2026 $14.4M (up 243% YoY) driven by milestone revenue.
- R&D expense $9.6M (down 24% YoY); G&A expense $6.6M (down 16% YoY).
- Amortization included $2.9M non-cash impairment from discontinued small-molecule programs.
- Cash operating expenses (non-GAAP) $12.3M, down from $14.7M YoY.
- 2026 revenue guidance raised; management highlights OmniUltra launch and partner progress.

## SEC filing metadata
- accession: 0001846253-26-000035
- form_type: 8-K
- ticker: OABI
- cik: 0001846253
- company_name: OmniAb, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1846253/000184625326000035/0001846253-26-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1846253/000184625326000035/oabi-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001846253-26-000035
- JSON: https://secwatch.observer/filing/0001846253-26-000035.json
- Plain text: https://secwatch.observer/filing/0001846253-26-000035.txt

## Source-grounded claims
- claim_id: d74fe464ad87bf2ab415e1dd1cb8d66ae1339a7c
  claim: OmniAb, Inc. reported the three months ended March 31, 2026 results: revenue $14.4 million. Guidance raised.
  evidence_excerpt: as demonstrated by the launch of OmniUltra TM and our xPloration ® partner access program. ” First Quarter 2026 Financial Results Revenue for the first quarter of 2026 was $14.4 million , compared with $4.2 million for the same period in 2025 , with the increase primarily related to milestone revenue . Research and development expense was $9.6 million for the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1846253/000184625326000035/0001846253-26-000035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.